Philip Chen, chairman of the Taipei Exchange, discusses the capital market condition, elaborates on the significance of biotech, and shares the competitive advantages of innovation companies listing on TPEx. Chen goes on to highlight the importance of assessment criteria and transparency in decreasing the information asymmetry, a key mission of the organization.
For biotech companies, the costs involved in IPO on TPEx is more realistic than those on other major international markets. Besides, TPEx listing requirements for biotech enterprises are more relaxed compared to those of Hong Kong Stock Exchange and Shanghai Stock Exchange.
